Yaoming biology and AC immune company of Switzerland reach an exclusive strategic cooperation

With the rich experience accumulated in the field of innovative biological products production, such as wuxiup, an ultra efficient continuous production process platform independently developed by Yaoming biology, AC immune company can better develop products in the field of central nervous system, reduce the cost of biological drug development, and AC immune company is authorized to use wuxibody of Yaoming biology Gamma Many biopharmaceutical technology platforms with independent intellectual property rights have been developed to develop a new generation of bispecific antibody drug discovery biology, which has become the preferred partner for the bioprocess development and production of AC immune company, providing strong support for it December 19, 2018 / Meitong society / -- the world's leading open biopharmaceutical technology platform company, Wuxi biology, 2269 HK) and AC immune SA, a Swiss clinical stage biopharmaceutical company that has established rich R & D pipelines around neurodegenerative diseases, announced on December 19 that the two sides have reached exclusive strategic cooperation in the field of biopharmaceutical discovery, development and production Through this exclusive strategic cooperation, AC Immunone will take advantage of the first-class technical ability and strong production capacity in traditional and innovative biological product production and supply fields, better develop products in the field of central nervous system, and obtain authorization to use multiple biopharmaceutical technology platforms with independent intellectual property rights, including the dual specific antibody development technology platform wuxibody Gamma And wuxiup, an ultra efficient continuous cell culture production platform At the same time, Yaoming bio will become the preferred partner for the biological process development and production of AC immune company, providing strong support for the discovery of its strong product pipeline, pre clinical and clinical trial sample supply According to the cooperation agreement, the two sides will also make full use of the excellent antibody discovery technology platform of AC immune company to develop candidate drug service global enterprises, and explore innovative biological drugs for diseases outside the central nervous system At the same time, Yuxi vaccines, a vaccine R & D and production service company jointly established by Yaoming biology and Haili biology, will also enable the vaccine product line of AC immune company to explore the Chinese market "We are pleased to enter into exclusive strategic cooperation with Yaoming bio, the leader of China's biopharmaceutical industry." Professor Andrea Pfeifer, CEO of AC immune company, said, "AC immune company is committed to becoming a global leader in precision medicine for neurodegenerative diseases and providing effective solutions for Alzheimer's disease treatment In the process of realizing this great vision, the Chinese market and Chinese enterprises will play a crucial role " "Through the cooperation with Genentech and Lilly, AC immune has proved its global leading position in the field of central nervous system We are very excited to establish a comprehensive and exclusive strategic partnership with AC immune The success of central nervous system biopharmaceuties depends largely on competitive production technology and low production cost Wuxibody, a bispecific antibody development platform with independent intellectual property rights of YaoMing biology Gamma And the ultra efficient continuous cell culture production process platform wuxiup not only breaks through the limitations of similar technology platforms, but also has the advantages of significantly reducing development and production costs, which will effectively promote the commercialization process of the cooperation project " Dr Chen Zhisheng, CEO of YaoMing biology, said, "we will continue to invest in the development of leading innovative technologies in the world, accelerate and change the development and production process of biopharmaceuticals, and empower such high-quality global partners as AC immune company to provide innovative biopharmaceuticals with high quality standards for more unmet clinical needs, so as to benefit patients around the world." About AC immune SA AC immune SA is a Swiss clinical stage biopharmaceutical company listed on Nasdaq, committed to becoming a global leader in neurodegenerative disease precision medicine The company designs, discovers and develops a range of therapeutic and diagnostic products to prevent and repair diseases caused by protein misfolding Based on two leading patent technology platforms, AC immune SA has developed antibodies, small molecule drugs and vaccines for a variety of neurodegenerative diseases represented by Alzheimer's disease The company's product line includes 9 treatment products and 3 candidate diagnosis products, 5 of which are in clinical trial stage Crenezumab, the company's fastest-growing product, is an all human IgG4 monoclonal antibody against β - amyloid protein It is currently in two phase III clinical trials to treat Alzheimer's disease The product has cooperated with Roche / Genentech worldwide Our partners include Lilly, Biogen, Janssen, Nestle health science, life molecular imaging (formerly Piramal imaging) and Essex bio technology For more information, please visit www.acimumune.com As a Hong Kong listed company, Yaoming bio (Stock Code: 2269 HK) is the world's leading open, integrated bio pharmaceutical capability and technology enabling platform The company provides a full range of end-to-end R & D services for global biopharmaceutical companies and biotechnology companies, helps anyone and any company to discover, develop and produce biopharmaceuticals, realizes the whole process from concept to commercial production, accelerates the global R & D process of biopharmaceuticals, reduces the cost of research and development, and benefits patients As of June 30, 2018, 187 comprehensive projects have been developed on the platform, including 98 in the preclinical research stage, 78 in the early clinical stage (phase I, phase II), 10 in the late clinical stage (phase III) and 1 in the commercial production stage It is estimated that by 2021, the total capacity of the company's planned biopharmaceutical production bases in China, Ireland, Singapore and the United States will be about 220000 liters, which will effectively ensure that the company will provide customers with biopharmaceuticals that meet global quality standards through a sound and strong global supply chain network.